Comparison of in vitro susceptibility of Sarcoptes scabiei var.hominis to topical 5%permethrin and topical 1% ivermectin

Authors

  • Nighat Akbar
  • Nadia Iftikhar

Keywords:

Scabies, Sarcoptes scabiei, ivermectin, permethrin, in vitro susceptibility

Abstract

Objective: To compare the in vitro susceptibility of Sarcoptes scabiei var.hominis to 5% permethrin and 1% ivermectin.Methods: A randomized, controlled trial was conducted in OPD, Dermatology Department, Military Hospital, Rawalpindi, Pakistan over a period of six months from December 17, 2014 to June 16, 2015.A total of 80 mites from 80 patients were taken. Mites were randomly allocated to two groups: group A (5% permethrin) and group B (1% ivermectin). 5% permethrin and 1% ivermectin were applied in a thin film over a glass slide. Live mites were gently transferred to the glass slide. These were inspected microscopically for leg movements at an hourly interval for 6 hours. Death was declared once all leg movements had ceased. All mites which died within 6 hours were considered as susceptible to drug, while mites having active leg movements even after 6 hours were considered as non-susceptible.Results: There were 35 (84.5%) mites which showed invitro susceptibility in the group A (5% permethrin), whereas all the mites from group B (1% ivermectin) were susceptible.Conclusion: The in vitro susceptibility was statistically significant (p=0.021) in both the groups. 1% ivermectin was better than 5% permethrin in terms of invitro susceptibility.

References

Fuller LC. Epidemiology of scabies. Curr Opin Infect Dis. 2013;26:123-6.

Heukelbach J, Mazigo HD, Ugbomoiko US. Impact of scabies in resource-poor communities. Curr Opin Infect Dis. 2013;26:127-32.

Hay RJ, Steer AC, Engelman D, Walton S. Scabies in the developing world--its prevalence, complications, and management. Clin Microbiol Infect. 2012;18:313-23.

Micali G, Lacarrubba F, Verzi AE, Nasca MR. Low-cost equipment for diagnosis and management of endemic scabies outbreaks in underserved populations. Clin Infect Dis. 2015;60:327-9.

Leung V, Miller M. Detection of scabies: A systematic review of diagnostic methods. Can J Infect Dis Med Microbiol. 2011;22:143-6.

Le Cleach L, Chosidow O. Commentary on "Interventions for treating scabies". Evid Based Child Health. 2011;6:1865-6.

Ranjkesh MR, Naghili B, Goldust M, Rezaee E. The efficacy of permethrin 5% vs. oral ivermectin for the treatment of scabies.Ann Parasitol. 2012;59:189-94.

Lokuge B, Kopczynski A, Woltmann A, Alvoen F, Connors C, Guyula T et al. Crusted scabies in remote Australia, a new way forward: lessons and outcomes from the East Arnhem Scabies Control Program.Med J Aust. 2014;200:644-8.

Gonzalez P, Gonzalez F, Ueno K. Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr Pharm Biotechnol. 2012;13:1103-9.

Thuan NH, Pandey RP, Sohng JK. Recent advances in biochemistry and biotechnological synthesis of avermectins and their derivatives.ApplMicrobiolBiotechnol. 2014;98:7747-59.

Ōmura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445-55.

Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. Philos Trans R Soc LondB Biol Sci. 2014;369:20130434.

Rizvi SDA, Iftikhar N, Batool F. Effectiveness of oral ivermectin for eradicating infesting mites in patients of scabies. J Pak Assoc Dermatol. 2011;21:87-92.

Goldust M, Rezaee E, Raghifar R, Hemayat S. Treatment of scabies: the topicalivermectin vs. permethrin 2.5% cream. Ann Parasitol. 2013;59:79-84.

Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012;78:605-10.

Alasaad S, Rossi L, Heukelbach J, Perez JM, Hamarsheh O, Otiende M et al. The neglected navigating web of the incomprehensibly emerging and re-emerging Sarcoptes mite. Infect Genet Evol. 2014;17:253-9.

Andriantsoanirina V, Izri A, Botterel F, Foulet F, Chosidow O, Durand R. Molecular survey of knockdown resistance to pyrethroids in human scabies mites. Clin Microbiol Infect. 2014;20:O139-O141.

Dong K, Du Y, Rinkevich F, Nomura Y, Xu P, Wang L et al. Molecular biology of insect sodium channels and pyrethroid resistance. Insect Biochem Mol Biol. 2014;50:1-17.

Fischer K, Holt D, Currie B, Kemp D. Scabies: Important clinical consequences explained by new molecular studies.AdvParasitol. 2012;79:339-73.

Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol. 2012;1:132-9.

Aggarwal G, Rathore PK. Comparative study to test efficacy of topical permethrin and oral ivermectin in the management of scabies-a prospective randomized, single blinded controlled study. Nat J Integ ResMed. 2014;5:57-60.

Stoevesandt J, Carle L, Leverkus M, Hamm H. Control of large institutional scabies outbreaks.J Dtsch Dermatol Ges. 2012;10:637-47.

Worth C, HeukelbachJ, Fengler G, Walter B, Liesenfeld O et al. Acute morbidity associated with scabies and other ectoparasitoses rapidly improves after treatment with ivermectin. Pediatr Dermatol. 2012;29:430-6.

Elston CA, Elston DM. Treatment of common skin infections and infestations during pregnancy. Dermatol Ther. 2013;26:312-20.

Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J AmAcad Dermatol. 2014;70:417-e1.

Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S. Treatment for crusted scabies: limitations and side effects of treatment with ivermectin. J Nippon Med Sch. 2014;81:157-63.

Manjhi PK, Sinha RI, Kumar M, Sinha KI. Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. JClin DiagnRes. 2014;8: HC01-4. Journal of Pakistan Association of Dermatologists. 2016;26 (2):99-106.

Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol.2002;138:1618-9.

MiyajimaA, Komoda M, Akagi K, Yuzawa K, Yoshimasu T, Yamamoto Y et al. Experimental study of pharmacokinetics of external, whole‐body bathing application of ivermectin. J Dermatol. 2015;42:87-89.

Walton SF, Myerscough MR, Currie BJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg. 2000;94:92-6.

Downloads

Published

2016-11-17

How to Cite

1.
Akbar N, Iftikhar N. Comparison of in vitro susceptibility of Sarcoptes scabiei var.hominis to topical 5%permethrin and topical 1% ivermectin. J Pak Assoc Dermatol [Internet]. 2016Nov.17 [cited 2024Nov.2];26(2):99-106. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/49

Issue

Section

Original Articles

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)